Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.71 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 3/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3574806 | 0.90 | PTGES (0.85) | PTGESMCL1LDHAALDH1A1TSHR | |
| SCHEMBL3579996 | 0.85 | PTGES (0.78) | PTGESMCL1LDHAALDH1A1TSHR | |
| SCHEMBL3574862 | 0.85 | PTGES (0.77) | PTGESMCL1LDHAALDH1A1TSHR | |
| SCHEMBL3571596 | 0.84 | PTGES (0.72) | PTGESMCL1LDHAALDH1A1TSHR | |
| SCHEMBL3581438 | 0.83 | PTGES (1.00) | PTGESMCL1LDHAALDH1A1TSHR | |
| SCHEMBL3570895 | 0.82 | PTGES (0.83) | PTGESMCL1LDHAALDH1A1TSHR | |
| SCHEMBL3575240 | 0.82 | PTGES (0.76) | PTGESMCL1LDHAALDH1A1TSHR | |
| SCHEMBL3573824 | 0.82 | PTGES (0.72) | PTGESMCL1LDHAALDH1A1TSHR | |
| SCHEMBL4916779 | 0.82 | PTGES (0.53) | PTGESMCL1ALDH1A1TSHRKMT2A | |
| SCHEMBL4924661 | 0.80 | PTGES (0.67) | PTGESMCL1ALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705023-B2 | Indoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2010-04-27 | — | — | US | disclosed |
| EP-1778632-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070287715-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287715-A1 | Indoles Useful in the Treatment of Inflammation | PTGS1, IDO1, PTGES | PTGES 3/4885MCL1 1274/4885LDHA 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.